HBPCF OTC

Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2). Helix has established collaborative agreements to further its research. One such partnership with Moffitt Cancer Center involves studying L-DOS47's pharmacodynamics and exploring the advantages of co-administering it with immune checkpoint inhibitors. A separate collaboration with University Hospital Tuebingen focuses on evaluating L-DOS47's therapeutic impact on CEACAM6-positive cancer models, employing advanced preclinical metabolic imaging techniques. The company's corporate headquarters are located in Toronto, Canada.